Horizon 2020 funds high-potential innovation developed by SMEs through the SME Instrument. The SME Instrument gives Europe’s most successful entrepreneurs the chance to request funding for those breakthrough ideas with the potential to create new markets or revolutionise the existing ones.
Genomcore has been granted with Phase I to explore the international market for the implementation of a security framework in the maintenance of genetic data within personalized medicine in the public health system. The proposed model includes Genomcore Biomed, Genomcore Healthcare and Genom.care in combination with emerging methods for rapid genotyping. This allows clinical data storage as well as forensic use cases.
Genomcore also received the Seal of Excellence from the European Commission regarding its hybrid platform. And now, with the grant of the Phase I, the company is entitled to request a Phase II with funding up to 2 millions of Euros.